In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

Wylie said: "Ozempic (semaglutide) is a medication licensed for the management of type 2 diabetes. While it has shown ...

Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

Novo Nordisk A/S’s Rybelsus diabetes pill, a tablet version of Ozempic, reduced the risk of heart attacks and strokes in a large study that may drive broader use of the drug.

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.